FDA warns some Tydemy birth control pills may not be effective, could result in unexpected pregnancy

FDA warns some Tydemy birth control pills may not be effective, could result in unexpected pregnancy


Signage is seen outside the U.S. Food and Drug Administration headquarters in White Oak, Maryland, Aug. 29, 2020.

Andrew Kelly | Reuters

The U.S. Food and Drug Administration has warned that some Tydemy birth control pills may not be effective, several days after the manufacturer recalled two batches of the medication that were distributed in the U.S.

The FDA said the pills in question could result in unexpected pregnancy. The agency has not received any reports of adverse events related to Tydemy so far.

related investing news

This little-known pharma stock can rally 50%, Citi says

CNBC Pro

The manufacturer, Lupin Pharmaceuticals, announced a voluntary recall of two batches of Tydemy on July 29. The pills in those batches were distributed in the U.S. between June 3, 2022, and May 31, 2023.

CNBC Health & Science

Read CNBC’s latest health coverage:

Lupin, in a statement last week, said it recalled the batches because pills in one batch tested low for ascorbic acid and “high for a known impurity.” The company said a significant reduction in ascorbic acid could affect the product’s effectiveness.

Lupin said it is notifying wholesalers, distributors, drug chains and supermarkets of the problem and is working to get the affected pills off store shelves. Any store, distributor or wholesaler that has the affected pills in stock should immediately stop distributing them, the company said.

The batches of Tydemy that may not be effective come from lot numbers L200183 and L201560.

Lupin advised patients to continue taking their medication and immediately consult with their doctor about an alternative form of contraception.



Source

Rocket Lab rises 5% on record third-quarter revenue, launch backlog
Health

Rocket Lab rises 5% on record third-quarter revenue, launch backlog

Rocket Lab‘s stock rose as much as 5% on Tuesday after the space company posted record revenues in the third-quarter as it scoops up more launch deals and builds its backlog. The company, which makes satellites and rockets and provides launch services to its customers, on Monday reported revenue of $155 million for the period. […]

Read More
Millions more Americans could access obesity drugs after Trump’s deals with Eli Lilly, Novo Nordisk
Health

Millions more Americans could access obesity drugs after Trump’s deals with Eli Lilly, Novo Nordisk

US President Donald Trump makes an announcement in the Oval Office of the White House in Washington, DC on Nov. 6, 2025. Andrew Caballero-Reynolds | AFP | Getty Images President Donald Trump on Thursday struck landmark deals with Eli Lilly and Novo Nordisk that could mark a turning point in how many people can access […]

Read More
Startup Omada Health to start prescribing GLP-1s, other obesity medications as membership grows 
Health

Startup Omada Health to start prescribing GLP-1s, other obesity medications as membership grows 

The Omada Health logo is displayed on a smartphone screen. Sopa Images | Lightrocket | Getty Images Virtual care company Omada Health on Thursday said it will start prescribing GLP-1s and other obesity drugs and helping patients manage those medications. Omada plans to expand the offerings under its weight management program as its membership grows […]

Read More